查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2153478

2026-2034年全球癌症免疫療法藥物研發外包市場規模、佔有率、趨勢及成長分析報告

Global Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 200 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球癌症免疫療法藥物研發外包市場預計將從2025年的23億美元成長至2034年的56.2億美元，2026年至2034年的複合年成長率（CAGR）為10.42%。癌症免疫療法藥物研發外包市場預計將顯著成長，主要受創新癌症療法需求不斷成長以及藥物研發過程日益複雜化的推動。免疫療法已成為一種極具前景的癌症治療方法，它利用人體自身的免疫系統來靶向並摧毀癌細胞。隨著製藥公司加快藥物研發步伐並尋求降低成本，免疫療法研發活動的外包變得越來越普遍，這將推動該市場走上強勁成長的道路。

此外，免疫療法技術的進步正在推動市場創新。單株抗體、CAR-T細胞療法和免疫查核點抑制劑等新型療法的研發正在革新癌症治療，並為外包合作創造了新的機會。這些創新不僅提高了癌症治療的療效，也需要專業的知識和資源，因此外包對許多機構來說都極具吸引力。隨著對新型免疫療法和聯合治療的研究不斷深入，在改善患者預後和縮短藥物研發週期的預期推動下，癌症免疫療法藥物研發外包市場預計將進一步擴張。

此外，對合作和策略夥伴關係的日益重視正在塑造癌症免疫療法藥物研發外包的發展趨勢。隨著相關人員認知到利用外部專業知識和資源的重要性，製藥公司與合約研究組織（CRO）之間的合作日益普遍。這些夥伴關係使公司能夠獲得專業知識、先進技術和高效流程，從而增強其藥物研發管線。隨著癌症免疫療法藥物研發外包市場的不斷發展，對合作和創新的重視將在推動其未來成長方面發揮關鍵作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別未來預期趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球癌症免疫療法藥物研發外包市場：依服務類型分類

  • 市場分析、洞察與預測
  • 目標識別與檢驗
  • 鉛篩檢與表徵
  • 基於細胞的檢測

第5章 全球癌症免疫療法藥物研發外包市場：依癌症類型分類

  • 市場分析、洞察與預測
  • 肺癌
  • 乳癌
  • 結腸癌
  • 黑色素瘤
  • 攝護腺癌
  • 頭頸癌
  • 卵巢癌
  • 胰臟癌

第6章 全球癌症免疫療法藥物研發外包市場：依藥物類型分類

  • 市場分析、洞察與預測
  • 單株抗體
  • 免疫調節劑
  • 癌症疫苗和溶瘤病毒療法
  • 其他

第7章 全球癌症免疫療法藥物研發外包市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 中國
    • 日本
    • 韓國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Charles River Laboratories
    • WuXi AppTec
    • Evotec
    • Crown Bioscience
    • Eurofins Discovery
    • Pharmaron
    • Curia
    • Adimab
    • Abzena
    • BioDuro
    • Sygnature Discovery
    • Sai Life Sciences
    • Genscript
    • Creative Biolabs
    • Pharmatest
    • Domainex
    • Viva Biotech
    • Jubilant Biosys
    • Aragen Life Sciences
    • Eurofins BioPharma Product Testing
簡介目錄
Product Code: VMR11211227

The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD 5.62 Billion in 2034 from USD 2.30 Billion in 2025, growing at a CAGR of 10.42% during 2026-2034.The cancer immunotherapy drug discovery outsourcing market is poised for significant growth, driven by the increasing demand for innovative cancer treatments and the rising complexity of drug development processes. Immunotherapy has emerged as a promising approach to cancer treatment, harnessing the body's immune system to target and destroy cancer cells. As pharmaceutical companies seek to accelerate their drug discovery efforts and reduce costs, the outsourcing of immunotherapy research and development activities is becoming increasingly common, positioning this market for robust expansion.

Moreover, advancements in immunotherapy technologies are driving innovation within the market. The development of novel therapeutic agents, such as monoclonal antibodies, CAR-T cell therapies, and immune checkpoint inhibitors, is revolutionizing cancer treatment and creating new opportunities for outsourcing partnerships. These innovations not only enhance the efficacy of cancer therapies but also require specialized expertise and resources, making outsourcing an attractive option for many organizations. As research continues to explore new immunotherapeutic approaches and combination therapies, the cancer immunotherapy drug discovery outsourcing market is likely to expand further, driven by the promise of improved patient outcomes and accelerated drug development timelines.

Additionally, the growing emphasis on collaboration and strategic partnerships is shaping the cancer immunotherapy drug discovery outsourcing landscape. As stakeholders recognize the value of leveraging external expertise and resources, the formation of alliances between pharmaceutical companies and contract research organizations (CROs) is becoming more prevalent. These partnerships enable companies to access specialized knowledge, advanced technologies, and efficient processes that can enhance the drug discovery pipeline. As the cancer immunotherapy drug discovery outsourcing market continues to evolve, the focus on collaboration and innovation will play a crucial role in driving its future growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Service Type

  • Target Identification and Validation
  • Lead Screening and Characterization
  • Cell-based Assays

By Cancer Type

  • Lung
  • Breast
  • Colorectal
  • Melanoma
  • Prostate
  • Head and Neck
  • Ovarian
  • Pancreatic

By Drug Type

  • Monoclonal Antibodies
  • Immunomodulators
  • Cancer Vaccines and Oncolytic Viral Therapy
  • Others

COMPANIES PROFILED

  • Charles River Laboratories, WuXi AppTec, Evotec, Crown Bioscience, Eurofins Discovery, Pharmaron, Curia, Adimab, Abzena, BioDuro, Sygnature Discovery, Sai Life Sciences, Genscript, Creative Biolabs, Pharmatest, Domainex, Viva Biotech, Jubilant Biosys, Aragen Life Sciences, Eurofins BioPharma Product Testing

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY SERVICE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Service Type
  • 4.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Lead Screening and Characterization Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Cell-based Assays Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY CANCER TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Cancer Type
  • 5.2. Lung Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Breast Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Colorectal Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Prostate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Head and Neck Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Ovarian Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.9. Pancreatic Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY DRUG TYPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Drug Type
  • 6.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Immunomodulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Cancer Vaccines and Oncolytic Viral Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Service Type
    • 7.2.2 By Cancer Type
    • 7.2.3 By Drug Type
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Service Type
    • 7.3.2 By Cancer Type
    • 7.3.3 By Drug Type
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Spain
    • 7.3.9 Russia
    • 7.3.10 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Service Type
    • 7.4.2 By Cancer Type
    • 7.4.3 By Drug Type
    • 7.4.4 China
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 India
    • 7.4.8 Australia
    • 7.4.9 South East Asia
    • 7.4.10 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Service Type
    • 7.5.2 By Cancer Type
    • 7.5.3 By Drug Type
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Service Type
    • 7.6.2 By Cancer Type
    • 7.6.3 By Drug Type
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL CANCER IMMUNOTHERAPY DRUG DISCOVERY OUTSOURCING INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Charles River Laboratories
    • 9.2.2 WuXi AppTec
    • 9.2.3 Evotec
    • 9.2.4 Crown Bioscience
    • 9.2.5 Eurofins Discovery
    • 9.2.6 Pharmaron
    • 9.2.7 Curia
    • 9.2.8 Adimab
    • 9.2.9 Abzena
    • 9.2.10 BioDuro
    • 9.2.11 Sygnature Discovery
    • 9.2.12 Sai Life Sciences
    • 9.2.13 Genscript
    • 9.2.14 Creative Biolabs
    • 9.2.15 Pharmatest
    • 9.2.16 Domainex
    • 9.2.17 Viva Biotech
    • 9.2.18 Jubilant Biosys
    • 9.2.19 Aragen Life Sciences
    • 9.2.20 Eurofins BioPharma Product Testing